Semaglutide is a GLP-1R agonist approved for treatment of type 2 diabetes (in doses 0.5-2.0 mg once weekly) and obesity (2.4 mg once weekly) [6,7]
DSIP was isolated by Schoenenberger and Monnier, who reported recovering it from the cerebral venous blood of rabbits during electrically induced sleep and published the characterisation in 1977
(Innopeptides) Long-term storage, delivery (penetration into tissues, safety of cell-penetrating segments) are still being worked out
Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone
Images/packaging/labels may vary due to manufacturing changes
Prioritise clinically meaningful doses, synergistic antioxidant partner ingredients, full ingredient transparency, drinkable formats for improved bioavailability, and UK manufacturing standards with proper purity testing